NRNP 6635 Psychopathology & Diagnostic Reasoning
Midterm Exam Prep Document | 2026/2027 Edition | 250
Verified Questions
NRNP 6635 Psychopathology & Diagnostic Reasoning Midterm Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation resource for NRNP 6635 Psychopathology &
Diagnostic Reasoning contains 250 verified questions with detailed rationales. Designed to align with
the 2026/2027 academic year curriculum, it covers essential topics in psychopathology, diagnostic
criteria, and clinical reasoning. Each question includes evidence-based explanations to reinforce
understanding and ensure exam readiness. This document is a must-have for nursing and mental health
students seeking a high pass guarantee.
Abstract:
This exam preparation document for NRNP 6635 Psychopathology & Diagnostic Reasoning is meticulously crafted
to support graduate nursing students in mastering the midterm examination. The 250 verified questions span the
full breadth of psychopathology, from neurodevelopmental disorders to personality disorders, with a strong
emphasis on diagnostic reasoning using the DSM-5-TR framework. Each question is accompanied by a detailed
rationale that explains the correct answer and systematically eliminates distractors, promoting deep conceptual
understanding. The content is organized by core content areas, including mood disorders, anxiety disorders,
psychotic disorders, and trauma-related disorders, with weightings that mirror the actual exam. Updated for the
2026/2027 academic year, this resource integrates the latest research and clinical guidelines, ensuring relevance
and accuracy. Students will benefit from the structured approach to differential diagnosis, comorbidity assessment,
and treatment planning, which are critical for both exam success and future clinical practice. The document also
addresses ethical considerations and cultural competence, reflecting the holistic nature of psychiatric care. With a
pass guarantee and A+ grading standard, this prep guide is an indispensable tool for achieving excellence in
psychopathology and diagnostic reasoning.
Content Area Overview:
Content Area Questions Key Topics Weight
Neurodevelopmental and 1-30 ADHD, Autism Spectrum, Intellectual 12%
Childhood Disorders Disability, Tic Disorders
Schizophrenia Spectrum and 31-65 Schizophrenia, Schizoaffective, Delusional 14%
Other Psychotic Disorders Disorder, Catatonia
Bipolar and Related Disorders 66-95 Bipolar I/II, Cyclothymia, 12%
Manic/Hypomanic Episodes
Depressive Disorders 96-130 MDD, PDD, PMDD, Disruptive Mood 14%
Dysregulation
Anxiety and 131-170 GAD, Panic, Social Anxiety, OCD, 16%
Obsessive-Compulsive Hoarding
Disorders
Trauma- and Stressor-Related 171-200 PTSD, Acute Stress, Adjustment Disorders, 12%
Disorders Dissociative Disorders
Personality Disorders 201-230 Cluster A/B/C, Borderline, Antisocial, 12%
Narcissistic
Page 1
,Diagnostic Reasoning and Ethics 231-250 Differential Diagnosis, Comorbidity, 8%
Cultural Formulation, Ethical Principles
Page 2
,Q1. A patient presents with persistent depressive symptoms and a history of multiple antidepressant
trials without adequate response. Which neurobiological mechanism is most likely implicated in
treatment-resistant depression?
A. Reduced hippocampal neurogenesis due to chronic glucocorticoid exposure
B. Overactivity of the default mode network (DMN) leading to rumination
C. Polymorphism in the serotonin transporter gene (5-HTTLPR) resulting in reduced synaptic
serotonin
D. Dysregulation of the kynurenine pathway with increased neurotoxic metabolites
Correct Answer: D. Dysregulation of the kynurenine pathway with increased neurotoxic metabolites
Rationale: The kynurenine pathway is increasingly recognized in treatment-resistant depression;
inflammation shifts tryptophan metabolism toward kynurenine, producing neurotoxic metabolites (e.g.,
quinolinic acid) that reduce neuroplasticity. While reduced hippocampal neurogenesis (A) is associated
with depression, it is a consequence rather than a primary mechanism of treatment resistance. DMN
overactivity (B) is linked to rumination but not specifically to treatment resistance. The 5-HTTLPR
polymorphism (C) influences antidepressant response but is not the most likely mechanism in this context.
Why Wrong:
A - Reduced hippocampal neurogenesis is a consequence of chronic stress, not a direct mechanism
of treatment resistance.
B - Default mode network overactivity is associated with rumination but not specifically with
treatment-resistant depression.
C - The 5-HTTLPR polymorphism affects antidepressant metabolism but is not the primary
mechanism in treatment resistance.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6; Dantzer, R. (2018).
Role of the Kynurenine Pathway in Depression.
Q2. A clinician is evaluating a patient with a history of recurrent, unexpected panic attacks and
persistent worry about having additional attacks. The patient also reports avoidance of situations
where escape might be difficult. According to DSM-5-TR, which diagnosis should be considered
first?
A. Panic Disorder
B. Agoraphobia
C. Panic Disorder with Agoraphobia
D. Generalized Anxiety Disorder
Correct Answer: C. Panic Disorder with Agoraphobia
Rationale: DSM-5-TR allows for the diagnosis of both panic disorder and agoraphobia when criteria for
both are met. The patient has recurrent unexpected panic attacks (panic disorder) and fear/avoidance of
situations (agoraphobia). Option A (panic disorder alone) ignores the agoraphobic avoidance. Option B
(agoraphobia alone) would require that panic attacks are not present or are only situational. Option D
(GAD) involves excessive worry about multiple topics, not specifically panic attacks.
Why Wrong:
A - Panic Disorder alone does not capture the significant avoidance behavior.
B - Agoraphobia alone is diagnosed only if panic attacks are absent or exclusively situational.
D - Generalized Anxiety Disorder is characterized by chronic worry, not panic attacks.
Reference: American Psychiatric Association. (2022). DSM-5-TR, Panic Disorder and Agoraphobia
criteria.
Page 3
, Q3. A patient with schizophrenia has persistent negative symptoms despite adequate antipsychotic
treatment. Which pharmacological augmentation strategy is most supported by current evidence?
A. Addition of a selective serotonin reuptake inhibitor
B. Addition of a second-generation antipsychotic with high D2 affinity
C. Addition of a glutamatergic agent such as glycine or D-cycloserine
D. Addition of a mood stabilizer like lamotrigine
Correct Answer: C. Addition of a glutamatergic agent such as glycine or D-cycloserine
Rationale: Negative symptoms are linked to glutamatergic dysfunction; agents that enhance NMDA
receptor function (e.g., glycine, D-cycloserine) have shown modest benefit in clinical trials. SSRIs (A) are
ineffective for primary negative symptoms. Adding another antipsychotic (B) may worsen side effects
without efficacy. Lamotrigine (D) has limited evidence for negative symptoms and is more often used for
mood stabilization.
Why Wrong:
A - SSRIs have not demonstrated efficacy for primary negative symptoms in schizophrenia.
B - Adding another antipsychotic increases side effects without proven benefit for negative
symptoms.
D - Lamotrigine is not well-supported for negative symptoms; its use is primarily in mood disorders.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16; Goff, D.C. (2020).
Glutamatergic agents for negative symptoms.
Q4. A patient presents with a history of multiple psychiatric hospitalizations, unstable relationships,
impulsivity, and recurrent self-harm. The patient reports chronic feelings of emptiness and transient
stress-related paranoia. Which personality disorder is most consistent with this presentation?
A. Histrionic Personality Disorder
B. Borderline Personality Disorder
C. Antisocial Personality Disorder
D. Schizotypal Personality Disorder
Correct Answer: B. Borderline Personality Disorder
Rationale: The combination of emotional instability, impulsivity, self-harm, chronic emptiness, and
transient paranoia is classic for borderline personality disorder (BPD). Histrionic PD (A) involves
attention-seeking but not self-harm or paranoia. Antisocial PD (C) features disregard for others and lack
of remorse, not self-harm. Schizotypal PD (D) includes odd beliefs and perceptual distortions, not
self-harm or emptiness.
Why Wrong:
A - Histrionic personality disorder is characterized by attention-seeking and emotionality, not
self-harm or paranoia.
C - Antisocial personality disorder involves exploitation and lack of remorse, not self-harm or
emptiness.
D - Schizotypal personality disorder includes odd thinking and perceptual disturbances, not
self-harm.
Reference: DSM-5-TR, Borderline Personality Disorder diagnostic criteria; Gunderson, J.G. (2018).
Handbook of Good Psychiatric Management for BPD.
Page 4
Midterm Exam Prep Document | 2026/2027 Edition | 250
Verified Questions
NRNP 6635 Psychopathology & Diagnostic Reasoning Midterm Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation resource for NRNP 6635 Psychopathology &
Diagnostic Reasoning contains 250 verified questions with detailed rationales. Designed to align with
the 2026/2027 academic year curriculum, it covers essential topics in psychopathology, diagnostic
criteria, and clinical reasoning. Each question includes evidence-based explanations to reinforce
understanding and ensure exam readiness. This document is a must-have for nursing and mental health
students seeking a high pass guarantee.
Abstract:
This exam preparation document for NRNP 6635 Psychopathology & Diagnostic Reasoning is meticulously crafted
to support graduate nursing students in mastering the midterm examination. The 250 verified questions span the
full breadth of psychopathology, from neurodevelopmental disorders to personality disorders, with a strong
emphasis on diagnostic reasoning using the DSM-5-TR framework. Each question is accompanied by a detailed
rationale that explains the correct answer and systematically eliminates distractors, promoting deep conceptual
understanding. The content is organized by core content areas, including mood disorders, anxiety disorders,
psychotic disorders, and trauma-related disorders, with weightings that mirror the actual exam. Updated for the
2026/2027 academic year, this resource integrates the latest research and clinical guidelines, ensuring relevance
and accuracy. Students will benefit from the structured approach to differential diagnosis, comorbidity assessment,
and treatment planning, which are critical for both exam success and future clinical practice. The document also
addresses ethical considerations and cultural competence, reflecting the holistic nature of psychiatric care. With a
pass guarantee and A+ grading standard, this prep guide is an indispensable tool for achieving excellence in
psychopathology and diagnostic reasoning.
Content Area Overview:
Content Area Questions Key Topics Weight
Neurodevelopmental and 1-30 ADHD, Autism Spectrum, Intellectual 12%
Childhood Disorders Disability, Tic Disorders
Schizophrenia Spectrum and 31-65 Schizophrenia, Schizoaffective, Delusional 14%
Other Psychotic Disorders Disorder, Catatonia
Bipolar and Related Disorders 66-95 Bipolar I/II, Cyclothymia, 12%
Manic/Hypomanic Episodes
Depressive Disorders 96-130 MDD, PDD, PMDD, Disruptive Mood 14%
Dysregulation
Anxiety and 131-170 GAD, Panic, Social Anxiety, OCD, 16%
Obsessive-Compulsive Hoarding
Disorders
Trauma- and Stressor-Related 171-200 PTSD, Acute Stress, Adjustment Disorders, 12%
Disorders Dissociative Disorders
Personality Disorders 201-230 Cluster A/B/C, Borderline, Antisocial, 12%
Narcissistic
Page 1
,Diagnostic Reasoning and Ethics 231-250 Differential Diagnosis, Comorbidity, 8%
Cultural Formulation, Ethical Principles
Page 2
,Q1. A patient presents with persistent depressive symptoms and a history of multiple antidepressant
trials without adequate response. Which neurobiological mechanism is most likely implicated in
treatment-resistant depression?
A. Reduced hippocampal neurogenesis due to chronic glucocorticoid exposure
B. Overactivity of the default mode network (DMN) leading to rumination
C. Polymorphism in the serotonin transporter gene (5-HTTLPR) resulting in reduced synaptic
serotonin
D. Dysregulation of the kynurenine pathway with increased neurotoxic metabolites
Correct Answer: D. Dysregulation of the kynurenine pathway with increased neurotoxic metabolites
Rationale: The kynurenine pathway is increasingly recognized in treatment-resistant depression;
inflammation shifts tryptophan metabolism toward kynurenine, producing neurotoxic metabolites (e.g.,
quinolinic acid) that reduce neuroplasticity. While reduced hippocampal neurogenesis (A) is associated
with depression, it is a consequence rather than a primary mechanism of treatment resistance. DMN
overactivity (B) is linked to rumination but not specifically to treatment resistance. The 5-HTTLPR
polymorphism (C) influences antidepressant response but is not the most likely mechanism in this context.
Why Wrong:
A - Reduced hippocampal neurogenesis is a consequence of chronic stress, not a direct mechanism
of treatment resistance.
B - Default mode network overactivity is associated with rumination but not specifically with
treatment-resistant depression.
C - The 5-HTTLPR polymorphism affects antidepressant metabolism but is not the primary
mechanism in treatment resistance.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6; Dantzer, R. (2018).
Role of the Kynurenine Pathway in Depression.
Q2. A clinician is evaluating a patient with a history of recurrent, unexpected panic attacks and
persistent worry about having additional attacks. The patient also reports avoidance of situations
where escape might be difficult. According to DSM-5-TR, which diagnosis should be considered
first?
A. Panic Disorder
B. Agoraphobia
C. Panic Disorder with Agoraphobia
D. Generalized Anxiety Disorder
Correct Answer: C. Panic Disorder with Agoraphobia
Rationale: DSM-5-TR allows for the diagnosis of both panic disorder and agoraphobia when criteria for
both are met. The patient has recurrent unexpected panic attacks (panic disorder) and fear/avoidance of
situations (agoraphobia). Option A (panic disorder alone) ignores the agoraphobic avoidance. Option B
(agoraphobia alone) would require that panic attacks are not present or are only situational. Option D
(GAD) involves excessive worry about multiple topics, not specifically panic attacks.
Why Wrong:
A - Panic Disorder alone does not capture the significant avoidance behavior.
B - Agoraphobia alone is diagnosed only if panic attacks are absent or exclusively situational.
D - Generalized Anxiety Disorder is characterized by chronic worry, not panic attacks.
Reference: American Psychiatric Association. (2022). DSM-5-TR, Panic Disorder and Agoraphobia
criteria.
Page 3
, Q3. A patient with schizophrenia has persistent negative symptoms despite adequate antipsychotic
treatment. Which pharmacological augmentation strategy is most supported by current evidence?
A. Addition of a selective serotonin reuptake inhibitor
B. Addition of a second-generation antipsychotic with high D2 affinity
C. Addition of a glutamatergic agent such as glycine or D-cycloserine
D. Addition of a mood stabilizer like lamotrigine
Correct Answer: C. Addition of a glutamatergic agent such as glycine or D-cycloserine
Rationale: Negative symptoms are linked to glutamatergic dysfunction; agents that enhance NMDA
receptor function (e.g., glycine, D-cycloserine) have shown modest benefit in clinical trials. SSRIs (A) are
ineffective for primary negative symptoms. Adding another antipsychotic (B) may worsen side effects
without efficacy. Lamotrigine (D) has limited evidence for negative symptoms and is more often used for
mood stabilization.
Why Wrong:
A - SSRIs have not demonstrated efficacy for primary negative symptoms in schizophrenia.
B - Adding another antipsychotic increases side effects without proven benefit for negative
symptoms.
D - Lamotrigine is not well-supported for negative symptoms; its use is primarily in mood disorders.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16; Goff, D.C. (2020).
Glutamatergic agents for negative symptoms.
Q4. A patient presents with a history of multiple psychiatric hospitalizations, unstable relationships,
impulsivity, and recurrent self-harm. The patient reports chronic feelings of emptiness and transient
stress-related paranoia. Which personality disorder is most consistent with this presentation?
A. Histrionic Personality Disorder
B. Borderline Personality Disorder
C. Antisocial Personality Disorder
D. Schizotypal Personality Disorder
Correct Answer: B. Borderline Personality Disorder
Rationale: The combination of emotional instability, impulsivity, self-harm, chronic emptiness, and
transient paranoia is classic for borderline personality disorder (BPD). Histrionic PD (A) involves
attention-seeking but not self-harm or paranoia. Antisocial PD (C) features disregard for others and lack
of remorse, not self-harm. Schizotypal PD (D) includes odd beliefs and perceptual distortions, not
self-harm or emptiness.
Why Wrong:
A - Histrionic personality disorder is characterized by attention-seeking and emotionality, not
self-harm or paranoia.
C - Antisocial personality disorder involves exploitation and lack of remorse, not self-harm or
emptiness.
D - Schizotypal personality disorder includes odd thinking and perceptual disturbances, not
self-harm.
Reference: DSM-5-TR, Borderline Personality Disorder diagnostic criteria; Gunderson, J.G. (2018).
Handbook of Good Psychiatric Management for BPD.
Page 4
